The UK Cystic Fibrosis Gene Therapy Consortium [ 7] is currently performing a phase 1/2 safety study using pGM169/GL67A [ 8] and will proceed to a multidose study in July 2011.
In this article, we proceed to a fine study of the transcriptome and report the location of 281 RYMV stress responsive sequences (RSR sequences identified by cDNA-AFLP).
Patients and methods: We proceed to a prospective study including all patients with septic shock at admission to ICU or secondary, over a 3-year period (January 2014 - December 2016).
The purpose of our study was to create a scale to collect subjective cognitive complaints of patients suffering from schizophrenia with Tunisian Arabic dialect as mother tongue and to proceed to a validation study of this scale.
If the phase II study is successful, we plan to proceed to a phase III study to establish survival non-inferiority in the de-intensified treatment arms, which will require European collaboration.
While exploratory studies do not require the extensive lead optimization, PK/PD, and toxicity analyses undertaken in therapeutic studies, they nonetheless should provide sufficient data to inform the decision of whether to proceed to a therapeutic animal study.
The phase II trial continues to recruit with a new primary outcome of progression-free survival in order to gain data on efficacy and help inform the decision to proceed to a phase III study with overall survival as the primary outcome.
As there is significant variation regarding lifespan when comparing different D. americana populations, it makes sense to proceed to a classical F2 association study.
We believe, therefore, that it is feasible to proceed to a sufficiently powered main study only with major modifications to the protocol; e.g. adapt the intensities and/or length of training.
Also, the decision to proceed to a repeat procedure in our study reflects contemporary real-world practice patterns.
